Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons V.D. de Jager

Publicaties

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

112P Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report

PS-20-007 PD-L1 expression in driver-mutated metastatic non-small cell lung cancer

PS-20-008 Predictive biomarker testing rates in patients with metastatic non-small cell lung cancer in The Netherlands

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands